Effect of Bifidobacterium on Irritable Bowel Syndrome (PBIBS)

Tohoku University

Status: Unknown

Conditions: Irritable Bowel Syndrome

Treatments: Drug: Placebo; Drug: Bifidobacterium breve

Study type: Interventional

Funder types: Other

Identifiers

NCT00737841

Probio-Bifid-IBS

Details and patient eligibility

About

There has been no data on effect of Bifidobacterium breve on symptoms of patients with irritable bowel syndrome (IBS). We hypothesized that Bifidobacterium breve is effective on symptoms of IBS patients.

Full description

There has been no data on effect of Bifidobacterium breve on symptoms of patients with irritable bowel syndrome (IBS). We hypothesized that Bifidobacterium breve is effective on symptoms of IBS patients. IBS patients will be enrolled via advertisement. Any IBS subtypes will not be rejected. They will take either 1.0 g of Bifidobacterium breve 3 times a day or same amount of placebo for 8 weeks. IBS symptoms and allied markers will be checked before, during, and after the administration.

Enrollment: 50 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Diagnosis of IBS with Rome II definition

Exclusion criteria

• Diagnosis of serious diseases (both physically and mentally)

Trial design

Primary purpose: Basic Science

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind

---

50 participants in 2 patient groups, including a placebo group

A

Experimental group

Description:

Bifidobacterium breve

Treatment:

Drug: Bifidobacterium breve

B

Placebo Comparator group

Description:

Placebo

Treatment:

Drug: Placebo